XML 116 R98.htm IDEA: XBRL DOCUMENT v3.10.0.1
Commitments and Contingencies - Additional Information (Detail)
1 Months Ended 12 Months Ended
Oct. 31, 2018
USD ($)
Suite
Sep. 30, 2018
USD ($)
Jul. 31, 2018
USD ($)
Jun. 30, 2018
USD ($)
Payment
Month
Quarter
Dec. 31, 2016
USD ($)
ft²
Aug. 31, 2015
ft²
Dec. 31, 2018
USD ($)
ft²
Dec. 31, 2017
USD ($)
Dec. 31, 2016
USD ($)
ft²
Settled Litigation [Member]                  
Commitments and Contingencies [Line Items]                  
Settlement date             September 4, 2018    
EXONDYS 51 [Member]                  
Commitments and Contingencies [Line Items]                  
Sales milestone recorded as an in-licensed rights assets         $ 1,000,000   $ 0 $ 6,600,000 $ 1,000,000
Collaboration and License Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Development milestone and up-front payments             142,400,000 22,000,000 47,600,000
Collaboration and License Agreement [Member] | Maximum [Member]                  
Commitments and Contingencies [Line Items]                  
Development, regulatory, up-front royalty and sales milestone payments             378,800,000    
BioMarin Pharmaceutical, Inc. [Member]                  
Commitments and Contingencies [Line Items]                  
Royalty expense             15,100,000 4,700,000  
Sales milestone recorded as an in-licensed rights assets             0    
CRO [Member]                  
Commitments and Contingencies [Line Items]                  
Cancellable future commitments             71,600,000    
CRO [Member] | Other Funding Commitments [Member]                  
Commitments and Contingencies [Line Items]                  
Expenditures incurred by CROs             $ 19,600,000 13,900,000 $ 8,500,000
Brammer [Member] | Manufacturing Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Advance upfront fee to be paid on execution of agreements       $ 20,000,000          
Number of non-refundable process equipment fee payments | Payment       2          
Required non refundable payments at each time of procurement of equipment       $ 5,000,000          
Quarterly capacity access fee payments   $ 5,000,000 $ 5,000,000 $ 10,000,000          
Portion of advance payment applied as credit to quarterly capacity access fees             one-tenth    
Quarterly capacity access fees due and payable beginning date       Jul. 01, 2019          
Quarterly capacity access fees due and payable ending date       Dec. 31, 2021          
Net capacity access fee       $ 8,000,000          
Manufacturing agreement term       6 years          
Successive renewal term of manufacturing agreement       2 years          
Minimum number of months prior to expiration of term for renewal | Month       24          
Maximum required additional quarters for remittance of capacity access fees before terminate agreement | Quarter       8          
Cash payment under agreements             $ 40,000,000    
Advance upfront fee paid on agreements       $ 20,000,000          
Process equipment fee paid $ 5,000,000   $ 5,000,000            
Brammer [Member] | Manufacturing Agreement [Member] | Other Current Assets [Member]                  
Commitments and Contingencies [Line Items]                  
Cash payment under agreements             5,000,000    
Brammer [Member] | Manufacturing Agreement [Member] | Other Non-current Asset [Member]                  
Commitments and Contingencies [Line Items]                  
Cash payment under agreements             $ 35,000,000    
Paragon [Member] | Paragon Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Number of dedicated clean room suites | Suite 2                
Number of additional clean room suites available on optional reserve | Suite 2                
Usage fees per annum per clean room suite $ 1,000,000                
Agreement expiration date Dec. 31, 2025                
Agreement expiration description             The term of the Paragon Collaboration Agreement will continue until the earlier of: (i) the latest expiration date of any commercial supply agreement in effect, or (ii) December 31, 2025. The Company has the ability to terminate the Paragon Collaboration Agreement prior to expiration, subject to potential additional financial consideration.    
Paragon [Member] | Paragon Agreement [Member] | Other Non-current Asset [Member]                  
Commitments and Contingencies [Line Items]                  
Clean room suite reservation fees payments $ 26,000,000                
Paragon [Member] | Paragon Agreement [Member] | Maximum [Member]                  
Commitments and Contingencies [Line Items]                  
Cean room suite reservation fees $ 48,000,000                
Percentage of credit on clean room use fee if threshold met 100.00%                
Aldevron LLC [Member] | Clinical and Commercial Supply Agreement [Member]                  
Commitments and Contingencies [Line Items]                  
Agreement expiration date             Dec. 31, 2019    
Agreement expiration description             The Company has an option to extend the CCSA to December 31, 2020 (the “2020 Option”) and other option to extend the term of the CCSA for an additional year to December 31, 2021 (the “2021 Renewal Right”).    
Percentage of prepayments credited back equal to batch invoice amount             50.00%    
Aldevron LLC [Member] | Clinical and Commercial Supply Agreement [Member] | Other Current Assets [Member]                  
Commitments and Contingencies [Line Items]                  
Prepayments to extend agreement term             $ 10,000,000    
Aldevron LLC [Member] | Clinical and Commercial Supply Agreement [Member] | Maximum [Member]                  
Commitments and Contingencies [Line Items]                  
Advance upfront fee to be paid on execution of agreements             $ 60,000,000    
Dublin [Member]                  
Commitments and Contingencies [Line Items]                  
Lease expiration date             2019-11    
Lease agreement entered date             2018-12    
Additional office and lab Space on lease | ft²             22,600    
Columbus [Member]                  
Commitments and Contingencies [Line Items]                  
Lease expiration date             2026-06    
Lease agreement entered date             2018-12    
Additional office and lab Space on lease | ft²             77,679    
Corvallis [Member]                  
Commitments and Contingencies [Line Items]                  
Lease expiration date             2020-12    
Lease terminated date month year             2018-06    
Sublease [Member] | Third Party One [Member]                  
Commitments and Contingencies [Line Items]                  
Additional rental space under amendment | ft²           15,077      
Lease agreement entered date           2015-08      
Lease expired date           2017-03      
Sublease [Member] | Third Party Two [Member]                  
Commitments and Contingencies [Line Items]                  
Additional rental space under amendment | ft²         7,461       7,461
Lease agreement entered date         2016-12        
Lease expired date         2017-12        
Sublease [Member] | Andover [Member]                  
Commitments and Contingencies [Line Items]                  
Additional rental space under amendment | ft²             23,102    
Lease agreement entered date description             March and July of 2018    
Lease expiration date             2020-12    
Sublease [Member] | Burlington [Member]                  
Commitments and Contingencies [Line Items]                  
Additional rental space under amendment | ft²             44,740    
Lease expiration date             2022-01    
Lease agreement entered date             2018-11    
Lease Agreements [Member]                  
Commitments and Contingencies [Line Items]                  
Lease expiration date             Sep. 30, 2025    
Total rental space | ft²             163,842    
Letters of credit amount issued             $ 1,000,000 $ 1,000,000